Original research
par
McGee, Meghan et al
Date de publication
2023
Géographie
Canada
Langue de la ressource
English
Texte disponible en version intégrale
Oui
Open Access / OK to Reproduce
Oui
Évalué par des pairs
Yes
L’objectif
To investigate excess costs of buprenorphine-naloxone due to unmerited market exclusivity (no legal patent or data protection) in Canada.
Constatations/points à retenir
If buprenorphine-naloxone cost $0.61 CAD (mean cost after the third generic entered) instead of $1.21 CAD per mg during the pre-generics period, public payers in British Columbia could have saved $5,016,220 CAD between 2011 and 2015. Unmerited 6 years of market exclusivity for brand-name buprenorphine-naloxone in Canada resulted in substantial excess costs.
La conception ou méthodologie de recherche
Interrupted time series examining cost changes before and after formularies listed generics
Mots clés
Policy/Regulatory
Barriers and enablers
Substitution/OAT
